EyeBio Email Format
Biotechnology ResearchEngland, United Kingdom51-200 Employees
In 2024, EyeBio became a wholly owned subsidiary of Merck following an acquisition, marking a significant corporate development. The company has pursued collaborations and partnerships to advance its retinal disease programs, reflecting ongoing efforts to translate research into clinical work.